Skip to main content

Anavex Life Sciences Stock Forecast, Price & News

-0.07 (-0.68 %)
(As of 05/13/2021 01:14 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume20,747 shs
Average Volume3.07 million shs
Market Capitalization$718.52 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVXL News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Anavex Life Sciences logo

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.


See More Headlines

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolNASDAQ:AVXL
Phone(800) 689-3939
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$0.45 per share


Net Income$-26,280,000.00




Market Cap$718.52 million
Next Earnings Date5/13/2021 (Confirmed)


Overall MarketRank

1.30 out of 5 stars

Medical Sector

845th out of 2,042 stocks

Commercial Physical Research Industry

15th out of 42 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Anavex Life Sciences (NASDAQ:AVXL) Frequently Asked Questions

Is Anavex Life Sciences a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Anavex Life Sciences stock.
View analyst ratings for Anavex Life Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Anavex Life Sciences?

Wall Street analysts have given Anavex Life Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Anavex Life Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Anavex Life Sciences?

Anavex Life Sciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,610,000 shares, an increase of 55.8% from the March 15th total of 3,600,000 shares. Based on an average daily volume of 3,970,000 shares, the days-to-cover ratio is currently 1.4 days.
View Anavex Life Sciences' Short Interest

When is Anavex Life Sciences' next earnings date?

Anavex Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Anavex Life Sciences

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) issued its earnings results on Wednesday, February, 10th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.01.
View Anavex Life Sciences' earnings history

How has Anavex Life Sciences' stock been impacted by Coronavirus?

Anavex Life Sciences' stock was trading at $3.32 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AVXL stock has increased by 209.0% and is now trading at $10.26.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AVXL?

5 brokers have issued 1 year price targets for Anavex Life Sciences' stock. Their forecasts range from $10.00 to $25.00. On average, they expect Anavex Life Sciences' share price to reach $17.60 in the next year. This suggests a possible upside of 71.5% from the stock's current price.
View analysts' price targets for Anavex Life Sciences
or view top-rated stocks among Wall Street analysts.

Who are Anavex Life Sciences' key executives?

Anavex Life Sciences' management team includes the following people:
  • Dr. Christopher U. Missling, Chairman, Pres, CEO & Sec. (Age 55, Pay $616.4k)
  • Ms. Sandra Boenisch CPA, CPA, CGA, Principal Financial Officer & Treasurer (Age 40, Pay $139.35k)
  • Mr. Stephan Toutain, Chief Operating Officer (Age 55)
  • Dr. Emmanuel O. Fadiran RPh, Ph.D., Sr. VP of Regulatory Affairs
  • Dr. Walter E. Kaufmann M.D., Chief Medical Officer
  • Clint Tomlinson, VP of Corp.
  • Dr. Adebayo Laniyonu, Sr. VP of Nonclinical Devel.

Who are some of Anavex Life Sciences' key competitors?

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), CytRx (CYTR), Sanchez Energy (SN), Novavax (NVAX), Geron (GERN), 385805 (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.28%), Geode Capital Management LLC (1.48%), Great Lakes Advisors LLC (0.98%), Russell Investments Group Ltd. (0.37%), Bank of New York Mellon Corp (0.29%) and Citigroup Inc. (0.26%). Company insiders that own Anavex Life Sciences stock include Elliot Favus and Peter DO Donhauser.
View institutional ownership trends for Anavex Life Sciences

Which institutional investors are selling Anavex Life Sciences stock?

AVXL stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., SNS Financial Group LLC, JPMorgan Chase & Co., Alliancebernstein L.P., Commonwealth Equity Services LLC, IFP Advisors Inc, Principal Financial Group Inc., and The Manufacturers Life Insurance Company .
View insider buying and selling activity for Anavex Life Sciences
or view top insider-selling stocks.

Which institutional investors are buying Anavex Life Sciences stock?

AVXL stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Great Lakes Advisors LLC, Geode Capital Management LLC, Citigroup Inc., Rafferty Asset Management LLC, UBS Group AG, Sheaff Brock Investment Advisors LLC, and Federated Hermes Inc..
View insider buying and selling activity for Anavex Life Sciences
or or view top insider-buying stocks.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anavex Life Sciences' stock price today?

One share of AVXL stock can currently be purchased for approximately $10.26.

How much money does Anavex Life Sciences make?

Anavex Life Sciences has a market capitalization of $718.52 million. The biotechnology company earns $-26,280,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Anavex Life Sciences have?

Anavex Life Sciences employs 20 workers across the globe.

What is Anavex Life Sciences' official website?

The official website for Anavex Life Sciences is

Where are Anavex Life Sciences' headquarters?

Anavex Life Sciences is headquartered at 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at (800) 689-3939 or via email at [email protected]

This page was last updated on 5/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.